西地那非治疗肺动脉高压的研究进展

New achievement of sildenafil therapy for pulmonary hypertension

本文综述西地那非治疗肺动脉高压的临床应用进展。西地那非是一种选择性的磷酸二酯酶抑制剂,通过减少环鸟苷酸(cGMP)的降解发挥其治疗作用。研究表明西地那非和吸入一氧化氮一样可以用于急性血管舒张试验。西地那非单独应用或者和其它药物联合应用已经证明对于各种类型的肺动脉高压具有一定疗效,而且因其价格比前列环素类药物及内皮素受体拮抗剂便宜,因此其临床应用前景是引人注目的。然而在西地那非治疗肺动脉高压的临床应用方面目前尚缺乏多中心、大例数的研究资料。

The following review discusses the achievement of sildenafil therapy for pulmonary hypertension. Sildenafil is a phosphodiestersase type 5 inhibitors which through inhibition of the breakdown of cGMP to enhance nitric oxide-dependent, cGMP-mediated pulmonary vasodilation. The use of sildenafil, alone or combined with prostacyclin or endothelin-receptor antagonist, has been showed that improvement in acute pulmonary hemodynamic and functional status.